Overview

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

Status:
Recruiting

Trial end date:
2026-04-01

Target enrollment:

Participant gender:

Summary

Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.

Phase:

Phase 3

Details

Lead Sponsor:

Colorado Prevention Center

Collaborators:

Bayer
Saint Luke's Hospital of Kansas City